Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells. Tarrado-Castellarnau M, Foguet C, Tarrago-Celada J, Palobart M, et al. Oncogene 2025 Jul 22. doi: 10.1038/s41388-025-03495.

Read + Share

Amedeo Smart

Independent Medical Education

Tarrado-Castellarnau M, Foguet C, Tarrago-Celada J, Palobart M, et al. Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells. Oncogene 2025 Jul 22. doi: 10.1038/s41388-025-03495.
PMID: 40696167